Key result
In elderly hypertensive patients with high cardiovascular risk, SBP 140-149 mmHg increased the risk of composite cardiovascular outcomes compared to SBP 130-139 mmHg (HR 1.36; 95% CI 1.06-1.75).
Why the study?
Does systolic blood pressure level affect the risk of cardiovascular outcomes and mortality in elderly hypertensive patients?
Cohort (n=9,655)
Does systolic blood pressure level affect the risk of cardiovascular outcomes and mortality in elderly hypertensive patients?
Hazard Ratio: 1.36 (95% CI 1.06–1.75)
In elderly hypertensive patients, an SBP of 130-139 mmHg was associated with the lowest risk of adverse outcomes, while SBP 140-149 mmHg increased risk in those with high baseline cardiovascular risk.
SBP associations in elderly hypertensives should not change targets; leaves open optimal thresholds pending randomized trials.
OBJECTIVE: The aim of this study was to investigate the association of systolic blood pressure (SBP) with cardiovascular disease and all-cause mortality among elderly hypertensive patients in northern China. PARTICIPANTS AND METHODS: In this prospective cohort study, 9655 elderly hypertensive patients from Kailuan study were followed up with the incidence of primary outcomes (composite outcomes including myocardial infarction, stroke, and all-cause death) and the incidence of secondary outcomes (stroke, myocardial infarction, and all-cause death). Patients were categorized into five groups on the basis of SBP levels: Q1 (SBP<130 mmHg), Q2 (130≤SBP<140 mmHg), Q3 (140≤SBP<150 mmHg), Q4 (150≤SBP<160 mmHg), and Q5 (SBP≥160 mmHg). RESULTS: During an average of 7.2±1.6 years of follow-up, patients in the group Q2 had the lowest incidence rates of composite outcomes. Q1 was not associated with a decreased risk of composite outcomes. Interestingly, compared with reference group Q2, the risk of composite outcomes [hazard ratio (HR): 1.36; 95% confidence interval (CI): 1.06-1.75] was significantly increased in the Q3 subgroup with high risk+very high risk for the incidence of ischemic cardiovascular disease (ICVD). Similarly, the risk of composite outcomes (HR: 1.25; 95% CI: 1.01-1.53 and HR: 1.35; 95% CI: 1.04-1.75) was significantly increased in Q4 subgroups, with both intermediate risk and high risk+very high risk for 10-year ICVD. CONCLUSION: Elderly hypertensive patients with a high risk of 10-year ICVD were still at a higher risk of developing adverse outcomes even with 140≤SBP<150 mmHg. SBP of less than 130 mmHg was not associated significantly with a reduced risk of developing adverse outcomes.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2018) conducted a cohort in hypertension (n=9,655). Systolic blood pressure 140-149 mmHg vs. Systolic blood pressure 130-139 mmHg was evaluated on composite outcomes including myocardial infarction, stroke, and all-cause death (HR 1.36, 95% CI 1.06-1.75). In elderly hypertensive patients with high cardiovascular risk, SBP 140-149 mmHg increased the risk of composite cardiovascular outcomes compared to SBP 130-139 mmHg (HR 1.36; 95% CI 1.06-1.75).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: